C4 Therapeutics Reports Second Quarter 2023 Financial Result

EstablishedExclusive Licensing Agreement for CFT8919, an EGFR L858R BiDAC™ Degrader, with Betta Pharmaceuticals in Greater China for NSCLC; U.S. IND Cleared

Related Keywords

China , Taiwan , United States , Macau , Hong Kong , American , Courtney Solberg , Mary Christian , Andrew Hirsch , Loraine Spreen , Len Reyno , Leonard Len Reyno , Therapeutics Inc , Exchange Commission , Drug Administration , International Conference On Malignant Lymphoma , Development Rd Expense , Betta Pharmaceuticals , Betta Pharmaceuticals In Greater China , American Society Of Clinical Oncology , Leadership Team , Corporate Communications Patient Advocacy , Establishedexclusive Licensing Agreement , Greater China , Escalation Data Expected , Chief Medical Officer , Senior Vice President , Cash Equivalents , Marketable Securities Total , Provide Runway , New Preclinical Data , International Conference , Malignant Lymphoma , Progress Poster , Clinical Oncology , Annual Meeting , Licensing Agreement , New Drug , Application Clearance Achieved , Betta Pharmaceutical Phase , Present Phase , Net Loss , Financial Guidance , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Consolidated Statement , Months Ended June , Corporate Communications , Patient Advocacy , Region ,